[en] OBJECTIVE: To evaluate the effect of transtympanic administration of tumor necrosis factor alpha (TNF-alpha) blockers to patients suffering from autoimmune inner ear disease (AIED). STUDY DESIGN: Nonrandomized, prospective pilot study. SETTING: Tertiary referral center. PATIENTS: 9 patients (4 men and 5 women; aged 51.22 +/- 13.11 years) presenting with autoimmune sensorineural hearing loss who responded to oral steroid treatment. Two groups of patients were treated. Group A consisted of 5 patients with AIED who could not be tapered off steroids. Group B consisted of 4 patients who were treated with intratympanic anti-TNF-alpha antibody therapy alone after a relapse of hearing loss following discontinuation of steroids. INTERVENTION: A Silverstein MicroWick local delivery system was placed in the round window niche and the patients were treated for 4 weeks with a weekly infusion of infliximab, a monoclonal antibody against TNF-alpha. MAIN OUTCOME MEASURE(S): Evaluation of hearing thresholds at 250-8000 Hz was performed before and after implantation of the Silverstein MicroWick and local delivery of the TNF-alpha blocker. RESULTS: Local administration of the TNF-alpha blocker allowed methylprednisolone to be tapered off without loss of hearing function in 4/5 steroid-dependent patients. Four additional patients were treated only with anti-TNF-alpha perfusion to the round window membrane without concomitant systemic administration of methylprednisolone. In 3 of these 4 patients, the pure tone average improved to 22.6 +/- 15.7 dB, resulting in hearing recovery comparable to treatment with systemic methylprednisolone. The 7 responding patients showed a significant reduction of recurrence of hearing loss to 0.028 +/- 0.072 episodes per month over the 4.3 +/- 2.4 months of the post-treatment period compared to 0.84 +/- 0.4 recurrences per week seen in the pretreatment period. CONCLUSIONS: The results of this pilot trial demonstrate that in patients with AIED, transtympanic delivery of the TNF-alpha blocker infliximab once weekly for 4 weeks allowed steroids to be tapered off, resulted in hearing improvement and reduced disease relapses. These preliminary efficacy and safety results appear encouraging enough to warrant further follow-up and studies for better determination of the potential clinical utility of local administration of infliximab for autoimmune hearing loss.
Disciplines :
Otolaryngology
Author, co-author :
Van Wijk, F.
Staecker, H.
Keithley, E.
Lefèbvre, Philippe ; Université de Liège > Département des sciences cliniques > Oto-rhino-laryngologie et audiophonologie
Language :
English
Title :
Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
Banerjee A, Parnes LS: Intratympanic corticosteroids for sudden idiopathic sensorineural hearing loss. Otol Neurotol 2005;26:878-881.
Boulassel MR, Deggouj N, Tomasi JP, Gersdorff M: Inner ear autoantibodies and their targets in patients with autoimmune inner ear diseases. Acta Otolaryngol 2001;121:28-34.
Cao MY, Dupriez VJ, Rider MH, Deggouj N, Gersdorff MC, Rousseau GG, Tomasi JP: Myelin protein Po as a potential autoantigen in autoimmune inner ear disease. FASEB J 1996;10:1635-1640.
Chandrasekhar SS: Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol 2001;22:18-23.
Chen MC, Harris JP, Keithley EM: Immunohistochemical analysis of proliferating cells in a sterile labyrinthitis animal model. Laryngoscope 1998;108:651-656.
Cohen S, Shoup A, Weisman MH, Harris J: Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. Otol Neurotol 2005;26:903-907.
Froehlich F, Fried M, Gonvers JJ, Saraga E, Thorens J, Pecoud A: Association of Crohn's disease and Cogan's syndrome. Dig Dis Sci 1994;39:1134-1137.
Harris JP, Ryan AF: Effect of a middle ear immune response on inner ear antibody levels. Ann Otol Rhinol Laryngol 1985;94:202-206.
Harris JP, Sharp PA: Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope 1990;100:516-524.
Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE: Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003;290:1875-1883.
Herr BD, Marzo SJ: Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg 2005;132:527-531.
Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R: Improved functional ability in patients with rheumatoid arthritis - long-term treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001;28:1983-1991.
Keithley EM, Ryan AF, Harris JP: Role of the round window membrane in middle ear immune responses. Acta Otolaryngol Suppl 1989;457:139-143.
Lefebvre PP, Staecker H: Steroid perfusion of the inner ear for sudden sensorineural hearing loss after failure of conventional therapy: a pilot study. Acta Otolaryngol 2002;122:698-702.
Matteson EL, Fabry DA, Facer GW, Beatty CW, Driscoll CL, Strome SE, McDonald TJ: Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis Rheum 2001;45:146-150.
Matteson EL, Tirzaman O, Facer GW, Fabry DA, Kasperbauer J, Beatty CW, McDonald TJ: Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol 2000;109:710-714.
Nash PT, Florin TH: Tumour necrosis factor inhibitors. Med J Aust 2005;183:205-208.
Parnes LS, Sun AH, Freeman DJ: Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999;109:1-17.
Ryan AF, Harris JP, Keithley EM: Immune-mediated hearing loss: basic mechanisms and options for therapy. Acta Otolaryngol Suppl 2002;548:38-43.
Ryan AF, Keithley EM, Harris JP: Autoimmune inner ear disorders. Curr Opin Neurol 2001;14:35-40.
Salley LH Jr, Grimm M, Sismanis A, Spencer RF, Wise CM: Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients. J Rheumatol 2001;28:1037-1040.
Siddiqui MA, Scott LJ: Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005;65:2179-2208.
Sismanis A, Wise CM, Johnson GD: Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg 1997;116:146-152.
Soliman AM, Zanetti F: Improvements of a method for testing autoantibodies in sensorineural hearing loss. Adv Otorhinolaryngol 1988;39:13-17.
Staecker H, Lefebvre PP: Autoimmune sensorineural hearing loss improved by tumor necrosis factor-alpha blockade: a case report. Acta Otolaryngol 2002;122:684-687.
ten Cate WJ, Bachor E: Autoimmune-mediated sympathetic hearing loss: a case report. Otol Neurotol 2005;26:161-165.
Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-1785.
Wang X, Truong T, Billings PB, Harris JP, Keithley EM: Blockage of immune-mediated inner ear damage by etanercept. Otol Neurotol 2003;24:52-57.
Welling DB: Clinical evaluation and treatment of immune-mediated inner ear disease. Ear Nose Throat J 1996;75:301-305.